ALC
Alcon Inc.
ALC's fundamentals are mixed: it turned 16% of its revenue into free cash flow, but its operating margin fell 5 points to 9.9%. At 55x earnings, it's trading above its usual 49x. Analysts expect strong earnings growth.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ALC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
ALC's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ALC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 19x | $71.83 | — |
| Cheap | 39x | $50.05 | -30% |
| Fair | 48x | $62.50 | -13% |
| Current | 55x | $71.83 | — |
| Expensive | 108x | $140 | +95% |
Historical ranges are pointers, not guarantees.
ALC's PE is in its fair range at 55x. If earnings grow as analysts expect, today's price would be 19x next year's earnings, in its cheap range.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ALC Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
ALC has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ALC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.85 | +196% |
| Q2 2026 | $1.30 | -40% |
| Q1 2026 | $1.65 | -27% |
| Q4 2025 | $1.97 | -3.9% |
| Q3 2025 | $2.10 | -11% |
| Q2 2025 | $2.15 | -3.6% |
| Q1 2025 | $2.25 | +6.1% |
| Q4 2024 | $2.05 | +4.1% |
| Q3 2024 | $2.35 | +161% |
ALC has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ALC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $2.8B | +8.7% |
| Q1 2026 | $2.7B | +7.3% |
| Q4 2025 | $2.7B | +8.6% |
| Q3 2025 | $2.6B | +6.5% |
| Q2 2025 | $2.6B | +4% |
| Q1 2025 | $2.5B | +0.6% |
| Q4 2024 | $2.5B | +6.4% |
| Q3 2024 | $2.5B | +5.4% |
ALC's revenue has grown year over year for 23 quarters in a row: $2.8B last quarter, up 8.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 0.4% | -9.1 points |
| Q1 2026 | 15% | -3.4 points |
| Q4 2025 | 12% | -4.3 points |
| Q3 2025 | 13% | -0.8 points |
| Q2 2025 | 9.5% | -3.2 points |
| Q1 2025 | 19% | +4 points |
| Q4 2024 | 16% | +6.9 points |
| Q3 2024 | 14% | +0.9 points |
ALC has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ALC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ALC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $414M | +11% |
| Q1 2026 | $273.6M | +12% |
| Q4 2025 | $457M | +46% |
| Q3 2025 | $538.7M | -12% |
| Q2 2025 | $372M | -9.3% |
| Q1 2025 | $244M | +23% |
| Q4 2024 | $313.2M | +186% |
| Q3 2024 | $613.2M | +69% |
ALC generated $1.7B in free cash flow over the past year, up 9.1% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ALC on cash flow, with more consistent year-over-year improvement.
ALC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -1.5M shares |
| 1 year | -1.8% | -9.2M shares |
| 3 years | -1.4% | -7M shares |
| 5 years | -0.9% | -4.5M shares |
| Available history | +0.1% | +500K shares |
ALC has 489M diluted shares, down 1.8% from a year ago, with $921M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q2 2026 | $289M |
| Q1 2026 | $73.5M |
| Q4 2025 | $308M |
| Q3 2025 | $250.5M |
| Q2 2025 | $126M |
| Q1 2025 | $33M |
| Q4 2024 | $2M |
| Q3 2024 | $3M |
ALC spent $921M buying back its own shares over the past year, about six times what it spent the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ALC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ALC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 1.4x | Healthy |
| Q1 2026 | 1.4x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.4x | Healthy |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | 1.4x | Healthy |
| Q4 2024 | 1.3x | Healthy |
| Q3 2024 | 1.4x | Healthy |
ALC's net debt is about 1.4 years of its operating earnings (EBITDA), about the same as a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over ALC on leverage, with a lower net debt burden relative to earnings.
ALC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.0 | Neutral |
| Stochastic | 69.9 | Neutral |
ALC's weekly RSI is 53 (neutral) and its Stochastic is 70 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ALC PE vs Healthcare Sector
| Metric | ALC | Sector median | Relative |
|---|---|---|---|
| PE | 55x | 26x | 114% above |
| PE % | 51 | 29 | 22 pts above |
ALC is trading at 55x earnings, a 114% premium to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ALC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $68.4 | 5.1% above |
| 20 week MA | $69.2 | 3.7% above |
| 50 week MA | $72.9 | 1.5% below |
| 100 week MA | $79.1 | 9.2% below |
| 200 week MA | $80.6 | 11% below |
ALC has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ALC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $57.4 | $64.9 | +13% |
| 2021 | $64.9 | $86.6 | +34% |
| 2022 | $86.6 | $67.8 | -22% |
| 2023 | $67.8 | $78.1 | +15% |
| 2024 | $78.1 | $85.7 | +9.6% |
| 2025 | $85.7 | $80.4 | -6.2% |
| 2026 YTD | $80.4 | $71.8 | -11% |
ALC has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.